<DOC>
	<DOC>NCT00189982</DOC>
	<brief_summary>The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.</brief_summary>
	<brief_title>Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subject must have participated and completed participation in Baxter's clinical study 060101 Subject or parent/legally authorized representative has provided written informed consent Subjects who have withdrawn from Baxter's Clinical Study 060101 prior to the termination of the study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
</DOC>